[Abstract Only] Randomized Trial: Triple Therapy Effective for the Treatment of Cystic Fibrosis

Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele – New England Journal of Medicine (link to abstract – $ for full-text)

Editorial: Realizing the Dream of Molecularly Targeted Therapies for Cystic Fibrosis (free)

Related Research: Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial – The Lancet (link to abstract – $ for full-text)

Commentary: Three-drug combo improves lung function in most common genetic form of cystic fibrosis – UT Southwestern Medical Center (free)

Related Commentary on Twitter

Triple treatment of CF patients with one Phe508del allele and one minimal function allele with elexacaftor, tezacaftor and ivacaftor resulted in sustained improvement in FEV1, sweat chloride, and the number of pulmonary exacerbations. #NACFC https://t.co/ATeGlBUWCp

— NEJM (@NEJM) October 31, 2019